Tempus AI

Tempus AI Raises $200M Series G

Precision medicine company using AI and machine learning to analyze clinical and molecular data for personalized cancer treatment

Key Highlights

• Funding Amount: $200M Series G
• Valuation: $8.1B
• Headquarters: Chicago, IL
• Founded: 2015
• Employees: 2000+
• Total Raised: $1.3B

About the Funding Round

Tempus AI has successfully closed $200M Series G in funding, marking a significant milestone in the company's growth trajectory. This investment will enable the company to accelerate product development, expand market reach, and strengthen its position in the ai/ml sector.

Investor Syndicate

The round was backed by a prestigious group of investors:

• NEA
• Baillie Gifford
• T. Rowe Price

This diverse group of investors brings not only capital but also strategic expertise and valuable networks that will help Tempus AI achieve its ambitious goals.

Market Opportunity

The ai/ml market continues to experience rapid growth, driven by increasing demand for innovative solutions and digital transformation across industries. Tempus AI's unique approach and proven technology position it well to capture significant market share in the coming years.

Company Background

Founded in 2015 and headquartered in Chicago, IL, Tempus AI has established itself as an innovative player in the ai/ml space. With 2000+ employees, the company has built a strong team focused on delivering exceptional value to customers.

Next Steps

With this new funding, Tempus AI plans to:

• Accelerate product development and innovation
• Expand into new markets and geographies
• Grow the team across engineering, sales, and operations
• Strengthen partnerships with key industry players
• Scale infrastructure to support rapid growth

Industry Impact

This funding round represents a strong vote of confidence in Tempus AI's vision and execution. The investment will help drive innovation in the ai/ml sector and create new opportunities for customers and partners.

For more information about Tempus AI, visit their website or contact their press office.